• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NOVOCURE, LTD. OPTUNE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NOVOCURE, LTD. OPTUNE Back to Search Results
Model Number TFH9100
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Convulsion/Seizure (4406)
Event Date 08/24/2020
Event Type  Injury  
Manufacturer Narrative
Novocure medical opinion is that the seizure was related to the underlying disease (gbm) and unrelated to optune therapy.Seizures were reported as adverse events in the ef-14 trial of optune together with temozolomide (tmz) compared to tmz alone in patients with newly diagnosed gbm in both arms of the trial (22% and 21% in optune/tmz and tmz arms respectively).None of these seizures were considered device or chemotherapy related by investigators.Seizures area known complication of gbm and have been reported as the presentation symptom in 27% of cases.During the course of the disease, 51% of patients will experience seizures (clin neurol neurosurg.2015; 139:166-171).
 
Event Description
A (b)(6) year old male patient with newly diagnosed glioblastoma (gbm) began optune therapy on (b)(6) 2020.Per medical record review, on (b)(6) 2020, patient was being treated for increased intracranial pressure with steroids (dexamethasone, 1 mg bid).At this time, steroid taper was begun with dexamethasone discontinued on (b)(6) 2020.On (b)(6) 2020, the patient experienced a grand mal seizure and was transported to the local emergency department.Patient's anti-seizure medication was increased and dexamethasone was restarted.Patient had a history of seizures and was taking anti-seizure medication at the time of the event.On (b)(6) 2020, head mri did not show gbm progression.Eeg showed no ongoing seizures.Per the prescribing physician, the cause of the seizure was likely due to underlying gbm and less likely due to optune.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTUNE
Type of Device
OPTUNE
Manufacturer (Section D)
NOVOCURE, LTD.
195 commerce way
portsmouth NH 03801
Manufacturer (Section G)
NOVOCURE, LTD.
195 commerce way
portsmouth NH 03801
Manufacturer Contact
sharon perez
195 commerce way
portsmouth, NH 03801
6033191907
MDR Report Key10590043
MDR Text Key208791558
Report Number3009453079-2020-00158
Device Sequence Number1
Product Code NZK
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P100034
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation Nurse
Type of Report Initial
Report Date 09/25/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Lay User/Patient
Device Model NumberTFH9100
Device Catalogue NumberN/A
Device Lot NumberN/A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/28/2020
Initial Date FDA Received09/25/2020
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured04/12/2016
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age71 YR
Patient Weight121
-
-